Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2024 10:01 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
May 02, 2024 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2024

May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental...
April 29, 2024 18:40 ET | Source: Genmab A/S

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient...
April 29, 2024 04:24 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
April 22, 2024 03:30 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
April 16, 2024 06:24 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
April 15, 2024 04:07 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
April 08, 2024 05:44 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
April 03, 2024 01:34 ET | Source: Genmab A/S

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart...
April 02, 2024 03:24 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...